Skip to content

Revvity RVTY Additional Paid-In Capital

Additional Paid-In Capital at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Danaher logo
DanaherDHR
WAT
Waters CorporationWAT
TEC
Bio-TechneTECH
Charles River Laboratories logo
Charles River LaboratoriesCRL
Quest Diagnostics logo
Quest DiagnosticsDGX

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's additional paid-in capital?
Revvity (RVTY) reported additional paid-in capital of $1.24B in Q1 2026.
How has Revvity's additional paid-in capital changed year-over-year?
Revvity's additional paid-in capital decreased by 36.7% year-over-year, from $1.95B to $1.24B.
What is the long-term trend for Revvity's additional paid-in capital?
Over 5 years (2020 to 2025), Revvity's additional paid-in capital has grown at a 54.6% compound annual growth rate (CAGR), from $148.1M to $1.31B.